The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5.
No abstract available

Keywords: Anti-TNF; Rheumatoid Arthritis; Treatment.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies / immunology*
  • Antibodies, Monoclonal / immunology*
  • Antirheumatic Agents / immunology*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Disease Progression
  • Female
  • Humans
  • Infliximab
  • Middle Aged
  • Time Factors

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab